Dr. Eduarta Holl is a clinical immunologist and translational researcher whose work focuses on advancing cancer immunotherapy, tumor microenvironment modulation, and diagnostic innovation. With 30 scientific publications, 2,947 citations, and an h-index of 17, her research demonstrates significant impact in oncology and immunology. Her contributions center on identifying novel therapeutic targets and strategies to enhance antitumor immunity, including the use of oncolytic viruses, immune checkpoint modulation, and dendritic cell–based approaches. She has played a key role in elucidating mechanisms of immune activation within tumor microenvironments and translating these findings into preclinical and early clinical applications. Additionally, her work in flow cytometry and diagnostic standardization has contributed to improving the accuracy and clinical utility of hematological malignancy assessment. Overall, her research integrates immunological discovery with translational and clinical applications to improve cancer treatment outcomes and diagnostic precision.